Zenas BioPharma Faces Investor Suit Over Post-IPO Plunge

By Sydney Price · April 17, 2025, 4:08 PM EDT

Autoimmune disease therapeutics company Zenas BioPharma Inc. was hit with a proposed shareholder class action alleging that its registration statement for its September 2024 initial public offering overstated the amount of...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Buathongsri v. Zenas BioPharma, Inc. et al

Case Number

1:25-cv-10988

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

April 16, 2025